Bank of New York Mellon
TCRT icon

Bank of New York Mellon’s Alaunos Therapeutics TCRT Stock Holding History

Bank of New York Mellon’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-685
Closed -$7.26K – 4309
2023
Q4 		$7.26K Hold
685
– – ﹤0.01% 4281
2023
Q3 		$13.5K Buy
685
+1
+0.1% +$43 ﹤0.01% 4277
2023
Q2 		$52.4K Hold
684
– – ﹤0.01% 4172
2023
Q1 		$64.7K Hold
684
– – ﹤0.01% 4143
2022
Q4 		$66.6K Hold
684
– – ﹤0.01% 4187
2022
Q3 		$177K Sell
684
-13
-2% -$3.78K ﹤0.01% 4061
2022
Q2 		$130K Sell
697
-3,884
-85% -$371K ﹤0.01% 4175
2022
Q1 		$448K Hold
4,581
– – ﹤0.01% 3777
2021
Q4 		$749K Buy
4,581
+4
+0.1% +$879 ﹤0.01% 3558
2021
Q3 		$1.25M Buy
4,577
+307
+7% +$93.9K ﹤0.01% 3276
2021
Q2 		$1.69M Sell
4,270
-2,374
-36% -$1.11M ﹤0.01% 3108
2021
Q1 		$3.59M Buy
6,644
+598
+10% +$372K ﹤0.01% 2611
2020
Q4 		$2.29M Sell
6,046
-115
-2% -$45.7K ﹤0.01% 2769
2020
Q3 		$2.33M Sell
6,161
-5
-0.1% -$2.21K ﹤0.01% 2580
2020
Q2 		$3.03M Buy
6,166
+623
+11% +$278K ﹤0.01% 2457
2020
Q1 		$2.04M Buy
5,543
+956
+21% +$495K ﹤0.01% 2532
2019
Q4 		$3.25M Buy
4,587
+276
+6% +$190K ﹤0.01% 2561
2019
Q3 		$2.77M Buy
4,311
+5
+0.1% +$3.97K ﹤0.01% 2573
2019
Q2 		$3.77M Buy
4,306
+468
+12% +$322K ﹤0.01% 2474
2019
Q1 		$2.22M Buy
3,838
+26
+0.7% +$10.9K ﹤0.01% 2726
2018
Q4 		$1.07M Sell
3,812
-193
-5% -$76.3K ﹤0.01% 3068
2018
Q3 		$1.92M Sell
4,005
-24
-0.6% -$10.3K ﹤0.01% 2851
2018
Q2 		$1.82M Sell
4,029
-103
-2% -$65.3K ﹤0.01% 2901
2018
Q1 		$2.43M Buy
4,132
+50
+1% +$31.2K ﹤0.01% 2702
2017
Q4 		$2.54M Sell
4,082
-41
-1% -$29.5K ﹤0.01% 2714
2017
Q3 		$3.8M Buy
4,123
+46
+1% +$40.9K ﹤0.01% 2474
2017
Q2 		$3.8M Buy
4,077
+88
+2% +$86.3K ﹤0.01% 2465
2017
Q1 		$3.79M Buy
3,989
+64
+2% +$59.6K ﹤0.01% 2465
2016
Q4 		$3.15M Buy
3,925
+174
+5% +$157K ﹤0.01% 2583
2016
Q3 		$3.17M Sell
3,751
-314
-8% -$252K ﹤0.01% 2478
2016
Q2 		$3.35M Buy
4,065
+145
+4% +$158K ﹤0.01% 2427
2016
Q1 		$4.36M Sell
3,920
-44
-1% -$45K ﹤0.01% 2243
2015
Q4 		$4.94M Sell
3,964
-123
-3% -$203K ﹤0.01% 2216
2015
Q3 		$5.52M Sell
4,087
-931
-19% -$1.54M ﹤0.01% 2179
2015
Q2 		$9.03M Buy
5,018
+1,250
+33% +$1.94M ﹤0.01% 2018
2015
Q1 		$6.09M Buy
3,768
+246
+7% +$365K ﹤0.01% 2204
2014
Q4 		$2.68M Sell
3,522
-77
-2% -$40.9K ﹤0.01% 2662
2014
Q3 		$1.43M Buy
3,599
+514
+17% +$248K ﹤0.01% 3091
2014
Q2 		$1.86M Buy
3,085
+10
+0.3% +$5.57K ﹤0.01% 2940
2014
Q1 		$2.11M Buy
3,075
+393
+15% +$263K ﹤0.01% 2845
2013
Q4 		$1.75M Buy
2,682
+167
+7% +$99.4K ﹤0.01% 2963
2013
Q3 		$1.49M Buy
2,515
+31
+1% +$14K ﹤0.01% 3024
2013
Q2 		$787K Buy
+2,484
New +$690K ﹤0.01% 3315

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Bank of New York Mellon's TCRT Position: Q1 2024 in Review

Bank of New York Mellon sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 685 shares — an estimated $7.26K sold.

Bank of New York Mellon first reported a position in TCRT in Q2 2013 and held it in 43 quarters. The position peaked at $9.03M in Q2 2015. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Bank of New York Mellon reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 685 Alaunos Therapeutics shares in Q1 2024, an estimated $7.26K.
  • Bank of New York Mellon first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 43 quarters.
  • Bank of New York Mellon's Alaunos Therapeutics position peaked at $9.03M in Q2 2015.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.